Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spyre Therapeutics, Inc. (SYRE : NSDQ)

• Company Description    Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based in WALTHAM, Mass. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $43.01 Daily Weekly Monthly 20 Day Moving Average: 732,624 shares Shares Outstanding: 78.54 (millions) Market Capitalization: $3,378.01 (millions) Beta: 3.08 52 Week High: $45.76 52 Week Low: $10.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 34.49% 35.67% 12 Week 28.58% 28.42% Year To Date 31.29% 30.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 CRESCENT STREET BUILDING 23 SUITE 105 - WALTHAM,MA 02453 USA ph: 617-651-5940 fax: 512-872-5121 eric.mcintyre@spyre.com http://www.spyre.com

• General Corporate Information    Officers Cameron Turtle, D.Phil - Chief Executive Officer Jeffrey W. Albers - Chairman of the Board Scott Burrows - Chief Financial Officer Peter Harwin - Director Michael Henderson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00773J202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 78.54 Most Recent Split Date: 9.00 (0.04:1) Beta: 3.08 Market Capitalization: $3,378.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 10.44% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.97 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 13.58% vs. Previous Quarter: -366.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -41.79 09/30/25 - -46.26 06/30/25 - -71.30 ROA 12/31/25 - -25.97 09/30/25 - -26.82 06/30/25 - -38.69 Current Ratio 12/31/25 - 13.25 09/30/25 - 10.90 06/30/25 - 6.49 Quick Ratio 12/31/25 - 13.25 09/30/25 - 10.90 06/30/25 - 6.49 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 7.21 09/30/25 - 3.86 06/30/25 - 4.98 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©